Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK.

Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10.

PMID:
22495074
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK.

AIDS. 2011 Jun 19;25(10):1281-8. doi: 10.1097/QAD.0b013e328347f3f1.

PMID:
21516030
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.

J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16.

PMID:
20554713
[PubMed - indexed for MEDLINE]
4.

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff.

PMID:
20101189
[PubMed - indexed for MEDLINE]
5.

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

AIDS. 2008 Sep 12;22(14):1719-28. doi: 10.1097/QAD.0b013e32830a5058.

PMID:
18690162
[PubMed - indexed for MEDLINE]
6.

Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes.

Räkel A, Renier G, Roussin A, Buithieu J, Mamputu JC, Serri O.

Diabetes Obes Metab. 2007 Jan;9(1):127-9. No abstract available.

PMID:
17199728
[PubMed - indexed for MEDLINE]
7.

Gliclazide inhibits differentiation-associated biologic events in human monocyte-derived macrophages.

Mamputu JC, Li L, Renier G.

Metabolism. 2006 Jun;55(6):778-85.

PMID:
16713438
[PubMed - indexed for MEDLINE]
8.

The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.

Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G.

Clin Endocrinol (Oxf). 2006 Apr;64(4):366-70.

PMID:
16584506
[PubMed - indexed for MEDLINE]
9.
11.

Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide.

Mamputu JC, Renier G.

Diabetes Obes Metab. 2004 Mar;6(2):95-103.

PMID:
14746574
[PubMed - indexed for MEDLINE]
12.

Lack of concordance between plasma markers of cardiovascular risk and intima-media thickness in patients with type 2 diabetes.

Moussavi N, Renier G, Roussin A, Mamputu JC, Buithieu J, Serri O.

Diabetes Obes Metab. 2004 Jan;6(1):69-77.

PMID:
14686966
[PubMed - indexed for MEDLINE]
13.

Antiatherogenic properties of metformin: the experimental evidence.

Mamputu JC, Wiernsperger NF, Renier G.

Diabetes Metab. 2003 Sep;29(4 Pt 2):6S71-6. Review.

PMID:
14502103
[PubMed - indexed for MEDLINE]
14.

Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells.

Renier G, Mamputu JC, Serri O.

Metabolism. 2003 Aug;52(8 Suppl 1):13-8. Review.

PMID:
12939734
[PubMed - indexed for MEDLINE]
15.

Monocyte adhesion in diabetic angiopathy: effects of free-radical scavenging.

Renier G, Mamputu JC, Desfaits AC, Serri O.

J Diabetes Complications. 2003 Mar-Apr;17(2 Suppl):20-9.

PMID:
12623165
[PubMed - indexed for MEDLINE]
16.
17.

Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein.

Mamputu JC, Renier G.

Metabolism. 2001 Jun;50(6):688-95.

PMID:
11398146
[PubMed - indexed for MEDLINE]
18.

Proliferative effect of lipoprotein lipase on human vascular smooth muscle cells.

Mamputu JC, Levesque L, Renier G.

Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2212-9.

PMID:
11031206
[PubMed - indexed for MEDLINE]
Free Article
20.

Lipoprotein lipase enhances human monocyte adhesion to aortic endothelial cells.

Mamputu JC, Desfaits AC, Renier G.

J Lipid Res. 1997 Sep;38(9):1722-9.

PMID:
9323582
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk